GSK (NYSE:GSK) Releases FY 2024 Earnings Guidance

GSK (NYSE:GSK) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 2.120-2.160 for the period, compared to the consensus estimate of 3.960. The company issued revenue guidance of $41.2 billion-$41.2 billion, compared to the consensus revenue estimate of $39.6 billion.

GSK Price Performance

GSK stock traded up $0.15 during mid-day trading on Friday, reaching $43.50. 4,048,068 shares of the company were exchanged, compared to its average volume of 3,498,257. The company has a fifty day simple moving average of $41.87 and a 200-day simple moving average of $39.14. GSK has a 12 month low of $33.33 and a 12 month high of $43.84. The company has a debt-to-equity ratio of 1.15, a current ratio of 0.87 and a quick ratio of 0.62. The firm has a market cap of $90.15 billion, a PE ratio of 15.76, a PEG ratio of 1.49 and a beta of 0.65.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.72 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). GSK had a return on equity of 51.54% and a net margin of 14.62%. The company had revenue of $10 billion for the quarter, compared to the consensus estimate of $9.79 billion. As a group, equities research analysts expect that GSK will post 4.13 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 11th. Stockholders of record on Friday, May 17th will be paid a $0.3762 dividend. This is a positive change from GSK’s previous quarterly dividend of $0.36. The ex-dividend date is Thursday, May 16th. This represents a $1.50 annualized dividend and a dividend yield of 3.46%. GSK’s dividend payout ratio (DPR) is presently 57.61%.

Analyst Ratings Changes

GSK has been the topic of several recent analyst reports. Citigroup upgraded GSK from a neutral rating to a buy rating in a research note on Tuesday, February 13th. Guggenheim upgraded GSK from a neutral rating to a buy rating in a research note on Monday, March 4th. Finally, Morgan Stanley initiated coverage on GSK in a research note on Tuesday, January 23rd. They issued an equal weight rating on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, GSK presently has an average rating of Moderate Buy.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.